Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 3

recruiting
3 977
countries
28
conditions
2 105

345 trials match your criteria

K-ras gene mutation+1

Recruiting

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Ovarian cancer recurrent

Recruiting

Evaluation of Raludotatug Deruxtecan With Carboplatin, Paclitaxel, or Bevacizumab in Relapsed High-grade Serous Ovarian, Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Squamous cell carcinoma of lung+8

Recruiting

A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327

Non-small cell lung cancer

Recruiting

Study of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Triple negative breast cancer

Recruiting

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Ovarian cancer

Recruiting

A Study of Carboplatin Given Directly into the Abdomen After Surgery in Elderly and Frail Patients with Ovarian Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Carboplatin

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.